Drugs / trimebutine 3-thiocarbamoylbenzenesulfonate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02276768 | Oct → Dec 2014 | cancer, colonic disorder | gicare Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01738425 | Nov 2012 → Apr 2013 | colonic disorder | gicare Pharma Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01926444 | Jul 2013 → Mar 2014 | cancer, colonic disorder | gicare Pharma Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trimebutine 3-thiocarbamoylbenzenesulfonate | “Trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) is a new drug intended to be used for the management of visceral pain in patients undergoing sedation-free, full colonoscopy.” PMID 25224876 ↗ Sep 2014 |
| Known as | GIC-1001 | “Trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) is a new drug intended to be used for the management of visceral pain in patients undergoing sedation-free, full colonoscopy.” PMID 25224876 ↗ Sep 2014 |
| Modality | Small molecule | — CHEMBL4297381 ↗ |
| Route | Oral | “GIC-1001 oral tablet” NCT01926444 ↗ |